Workflow
GROWN UP GROUP(01842)
icon
Search documents
植华集团(01842) - 致登记股东之通知信函及更改申请表格 - 刊发二零二五年中期报告的发佈通知
2025-09-29 01:05
Grown Up Group Investment Holdings Limited (the "Company") – Notice of publication of 2025 Interim Report (the "Current Corporate Communication") Grown Up Group Investment Holdings Limited 植華集團投資控股有限公司 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) (Stock Code 股份代號:1842) NOTIFICATION LETTER 通知信函 29 September 2025 Dear Registered Shareholder, Chairman and Executive Director Note: Corporate Communications include any document(s) issued or to be issued by the Company for the infor ...
植华集团(01842) - 2025 - 中期财报
2025-09-29 01:03
Financial Performance - Revenue for the six months ended June 30, 2025, was HKD 146,959,000, a decrease of 2% from HKD 150,847,000 in the same period of 2024[5] - The company reported a loss of HKD 8,466,000 for the six months ended June 30, 2025, compared to a loss of HKD 5,754,000 in the same period of 2024, representing a 47% increase in loss[5] - Basic and diluted loss per share for the period was HKD 0.71, compared to HKD 0.48 in the previous year, indicating a 48% increase in loss per share[8] - For the six months ended June 30, 2025, the company reported a total loss of HKD 9,634,000, compared to a total loss of HKD 6,063,000 for the same period in 2024, indicating an increase in losses of approximately 59%[11][12] - The company reported a net loss of approximately HKD 8.5 million for the six months ended June 30, 2025, compared to a net loss of approximately HKD 5.8 million for the same period in 2024, representing an increase in loss of about 46.6%[50] Assets and Liabilities - Total assets decreased to HKD 224,694,000 as of June 30, 2025, down from HKD 260,599,000 as of December 31, 2024, reflecting a 14% decline[9] - Current liabilities decreased to HKD 101,396,000 from HKD 128,720,000, a reduction of 21%[10] - The company's net asset value was HKD 121,531,000 as of June 30, 2025, down from HKD 131,165,000 at the end of 2024, a decrease of 7%[9] - The company's trade payables decreased to HKD 47,389,000 as of June 30, 2025, down 22% from HKD 60,781,000 as of December 31, 2024[43] - Trade receivables decreased to HKD 55,525,000 from HKD 75,405,000, a decline of 26.4%[33] Cash Flow and Investments - The company's cash flow from operating activities for the six months ended June 30, 2025, was HKD 10,387,000, significantly higher than HKD 2,421,000 for the same period in 2024, representing an increase of approximately 329%[12] - The net cash flow from investing activities for the six months ended June 30, 2025, was HKD 13,582,000, compared to HKD 2,930,000 for the same period in 2024, reflecting a substantial increase of approximately 363%[12] - The company's cash and cash equivalents increased by HKD 8,926,000 for the six months ended June 30, 2025, compared to an increase of HKD 9,638,000 in the same period of 2024[12] - The company acquired property, plant, and equipment amounting to approximately HKD 660,000, down from HKD 1,298,000 in the previous year, a decrease of 49.1%[31] Financial Ratios - The current ratio remained stable at 1.6 for both periods, indicating consistent liquidity management[5] - The debt-to-equity ratio improved to 37.4% as of June 30, 2025, compared to 39.0% at the end of 2024, showing a reduction in financial leverage[5] - The debt-to-equity ratio as of June 30, 2025, was 37.4%, a slight improvement from 39.0% as of December 31, 2024[58] Revenue and Profitability - The gross profit for the six months ended June 30, 2025, was HKD 23,054,000, an increase of 5% from HKD 21,865,000 in the same period of 2024[8] - The gross profit margin improved from approximately 14.5% for the six months ended June 30, 2024, to approximately 15.7% for the current reporting period[53] - Cost of goods sold decreased to HKD 108,494,000 from HKD 112,878,000, a reduction of 4.3%[24] Administrative and Other Expenses - Administrative expenses increased to approximately HKD 22.4 million for the current period, up from HKD 20.5 million for the same period in 2024, representing an increase of about 9.3%[55] - The company incurred financing costs of HKD 1,426,000 for the period, down from HKD 1,634,000 in the previous year, reflecting a 13% decrease[8] - Net financing costs rose to HKD (1,012,000) from HKD (717,000), representing an increase of 40.9%[25] Shareholder Information - The company did not declare an interim dividend for the six months ended June 30, 2025, consistent with the previous period[46] - The stock option plan adopted in May 2019 has no unexercised options as of June 30, 2025, and the total number of options available for grant remains at 100,000,000 shares[76] - As of June 30, 2025, Mr. Thomas Berg holds 371,000,000 shares, representing 30.92% of the issued share capital[77] - Stuart Ian Grimshaw owns 89,000,000 shares in GPG, accounting for 7.42% of the issued share capital[79] Market and Economic Outlook - The group anticipates a slowdown in global GDP growth in the second half of 2025, with inflation and employment rates showing mixed performance[69] - The group will adopt a prudent approach to business development to mitigate impacts from challenges such as U.S. tariff issues and rising material and labor costs in China[69] Employee and Training - As of June 30, 2025, the group had approximately 396 employees, a decrease from 412 employees as of June 30, 2024[63] - The group has provided regular training to employees to enhance their skills and knowledge related to product quality standards and safety[64]
植华集团(01842) - 股份发行人的证券变动月报表截止二零二五年八月三十一日止
2025-09-02 01:40
股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致:香港交易及結算所有限公司 公司名稱: 植華集團投資控股有限公司 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01842 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月底法 ...
植华集团发布中期业绩,净亏损846.6万港元,同比扩大47.1%
Zhi Tong Cai Jing· 2025-08-22 13:43
Core Viewpoint - The company reported a revenue of HKD 147 million for the six months ending June 30, 2025, reflecting a year-on-year decline of 2.6% and a net loss of HKD 8.466 million, which represents a 47.1% increase in losses compared to the previous year [1] Financial Performance - Revenue for the reporting period was HKD 147 million, down from HKD 150.8 million in the first half of 2024 [1] - The net loss increased to HKD 8.466 million, compared to a loss of HKD 5.76 million in the same period last year [1] - Basic loss per share was HKD 0.71 cents [1] Factors Contributing to Performance - The increase in net loss was primarily due to an unrealized fair value loss on listed securities amounting to approximately HKD 3.3 million, compared to a loss of HKD 2.2 million in the first half of 2024 [1] - Administrative expenses rose by approximately HKD 1.9 million, mainly due to the company's efforts to diversify its supply chain network and advance business development plans [1] - Recent developments in U.S. tariffs have negatively impacted these initiatives, leading to limited short-term visibility on expected benefits [1]
植华集团(01842)发布中期业绩,净亏损846.6万港元,同比扩大47.1%
智通财经网· 2025-08-22 12:18
Core Viewpoint - Zhihua Group (01842) reported a decline in revenue and an increase in net loss for the six months ending June 30, 2025, indicating challenges in its financial performance and market conditions [1] Financial Performance - Revenue for the period was HKD 147 million, a decrease of 2.6% year-on-year [1] - The net loss expanded to HKD 8.466 million, an increase of 47.1% compared to the previous year [1] - Basic loss per share was HKD 0.071 [1] Contributing Factors - The increase in net loss was primarily due to: - Unrealized fair value losses on listed securities amounting to approximately HKD 3.3 million, compared to a loss of HKD 2.2 million in the first half of 2024 [1] - Administrative expenses increased by approximately HKD 1.9 million, mainly due to the company's efforts to diversify its supply chain network and advance business development plans [1] Market Conditions - Recent developments in U.S. tariffs have negatively impacted the company's initiatives, leading to limited short-term visibility on expected benefits [1] - Revenue decreased from HKD 150.8 million in the first half of 2024 to HKD 147 million during the reporting period [1]
植华集团(01842) - 2025 - 中期业绩
2025-08-22 11:54
Financial Performance - Revenue for the six months ended June 30, 2025, was HKD 146,959,000, a decrease of 2% compared to HKD 150,847,000 for the same period in 2024[2] - The company reported a loss of HKD 8,466,000 for the current period, compared to a loss of HKD 5,754,000 in the previous year, indicating a worsening performance[2] - Gross profit for the period was HKD 23,054,000, up from HKD 21,865,000, reflecting a 5.4% increase year-over-year[4] - The company reported a net loss before tax of HKD 8,822,000, compared to HKD 6,271,000 in the previous year, indicating a worsening financial position[4] - Other comprehensive loss for the period totaled HKD 9,634,000, compared to HKD 6,063,000 in the previous year, representing an increase of 59.5%[4] - The basic loss per share was HKD 0.71, compared to HKD 0.48 in the same period last year, reflecting a 47.9% increase in losses per share[4] Assets and Liabilities - Total assets decreased to HKD 224,694,000 from HKD 260,599,000, representing a decline of approximately 13.8%[2] - Current liabilities were HKD 101,396,000, down from HKD 128,720,000, showing a reduction of about 21.2%[2] - The net asset value of the company was HKD 121,531,000, compared to HKD 131,165,000, indicating a decrease of approximately 7.3%[2] - The debt-to-asset ratio stood at 37.4%, slightly improved from 39.0% in the previous year[2] - The company’s total liabilities decreased from HKD 139,434 million to HKD 103,163 million, a reduction of about 26%[5] - The company’s non-current liabilities were recorded at HKD 103,163,000, down from HKD 129,434,000, showing a reduction of about 20.3%[6] Cash Flow and Financing - Cash and cash equivalents increased to HKD 61,573 million from HKD 54,056 million, showing a growth of around 14%[5] - Interest income from bank deposits amounted to HKD 414 million for the six months ended June 30, 2025, compared to HKD 917 million for the same period in 2024, representing a decrease of 54.8%[21] - Net financing costs were HKD 1,012 million for the six months ended June 30, 2025, compared to HKD 717 million for the same period in 2024, indicating an increase of 40.9%[21] - The annual interest rate for bank borrowings ranged from 1.5% to 5.3% as of June 30, 2025, compared to 3.8% to 5.7% as of December 31, 2024[42] Operational Focus - The company is focused on expanding its product lines in the medical-related products sector, which is expected to drive future revenue growth[7] - The group identified its main operational focus on the private label product segment, which includes design, development, procurement, manufacturing, and sales of various products[16] - The group’s operating activities are primarily concentrated on the private label product segment, as reviewed by key operating decision-makers[16] Employee and Corporate Governance - The company employed approximately 396 employees as of June 30, 2025, a decrease from approximately 412 employees on June 30, 2024[63] - The company has adhered to all corporate governance codes during the reporting period[72] - The audit committee has been established in accordance with listing rules and consists of three independent non-executive directors[79] Future Outlook - The company anticipates a slowdown in global GDP growth in the second half of 2025, with various competitive pressures expected[71] - The group has not disclosed specific future outlook or guidance in the provided content[16] Shareholder Information - The company reported no interim dividend for the six months ending June 30, 2025, consistent with the previous year[44] - There are no unexercised share options as of June 30, 2025, and no share options have been granted, exercised, cancelled, or lapsed during the reporting period[76] - The company and its subsidiaries did not buy, sell, or redeem any listed securities during the reporting period[77]
植华集团(01842.HK)将于8月22日召开董事会会议以审批中期业绩
Ge Long Hui· 2025-08-12 08:47
格隆汇8月12日丨植华集团(01842.HK)公布,公司将于2025年8月22日召开董事会会议,以(其中包括) 审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布,以及审议派发中期股息的建议(如 有)。 ...
植华集团(01842) - 董事会会议日期
2025-08-12 08:34
香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責,對其準確性或完整性亦不發表任何聲明,並明確表示概不就因本公告全部或 任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Grown Up Group Investment Holdings Limited 植 華 集 團 投 資 控 股 有 限 公 司 董事會會議日期 植華集團投資控股有限公司(「本公司」)董事(「董事」)會(「董事會」)謹此宣佈,本 公司謹訂於二零二五年八月二十二日( 星期五 )舉行董事會會議,藉以考慮及批准 ( 其中包括 )本公司及其附屬公司截至二零二五年六月三十日止六個月之未經審核 綜合中期業績及其刊發,以及考慮派發中期股息( 如有 )。 承董事會命 植華集團投資控股有限公司 主席兼執行董事 (於開曼群島註冊成立的有限公司) (股份代號:1842) 香港,二零二五年八月十二日 於本公告日期,執行董事為Thomas Berg先生、薛雅麗女士及Jan Ankersen先生; 以及獨立非執行董事為曾慶煊先生、黃繼興先生及陳霆畧先生。 Thom ...
植华集团(01842) - 股份发行人的证券变动月报表截止二零二五年七月三十一日止
2025-08-06 02:04
截至月份: 2025年7月31日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 致:香港交易及結算所有限公司 公司名稱: 植華集團投資控股有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01842 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 10,000 ...
植华集团(01842.HK)发盈警 预计中期亏损净额同比扩大约40%至50%
Jin Rong Jie· 2025-08-01 10:49
Core Viewpoint - The company, Zhihua Group (01842.HK), anticipates a significant increase in net losses for the first half of 2025, projecting a rise of approximately 40% to 50% compared to the net loss of about HKD 5.8 million for the first half of 2024 [1] Summary by Relevant Categories Financial Performance - The expected increase in net losses for the first half of 2025 is primarily attributed to a slight decline in revenue due to ongoing tariff pressures from the United States [1] - The company is set to recognize an unrealized loss of approximately HKD 3.3 million from listed securities investments in the first half of 2025, compared to a loss of HKD 2.2 million in the first half of 2024 [1] - Administrative expenses are projected to rise by about HKD 1.9 million, mainly due to the company's efforts to diversify its supply chain network and advance business development initiatives [1]